# The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma

> **NCT04415385** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 48 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT04415385
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2022-06-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2020-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04415385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04415385, "The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04415385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*